A detailed history of Royal Bank Of Canada transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 25,508 shares of NUVB stock, worth $73,718. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,508
Previous 16,881 51.1%
Holding current value
$73,718
Previous $49,000 18.37%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.3 - $3.83 $19,842 - $33,041
8,627 Added 51.1%
25,508 $58,000
Q2 2024

Aug 14, 2024

SELL
$2.58 - $3.69 $9,404 - $13,450
-3,645 Reduced 17.76%
16,881 $49,000
Q1 2024

Nov 05, 2024

BUY
$1.46 - $3.97 $5,321 - $14,470
3,645 Added 21.59%
20,526 $74,000
Q1 2024

May 15, 2024

SELL
$1.46 - $3.97 $67,698 - $184,084
-46,369 Reduced 69.32%
20,526 $74,000
Q4 2023

Feb 14, 2024

BUY
$0.96 - $1.53 $40,696 - $64,859
42,392 Added 173.01%
66,895 $101,000
Q3 2023

Nov 14, 2023

BUY
$1.26 - $2.1 $11,723 - $19,538
9,304 Added 61.21%
24,503 $32,000
Q2 2023

Aug 14, 2023

BUY
$1.56 - $1.84 $13,551 - $15,984
8,687 Added 133.4%
15,199 $27,000
Q1 2023

May 15, 2023

SELL
$1.6 - $2.48 $13,220 - $20,492
-8,263 Reduced 55.93%
6,512 $10,000
Q4 2022

Feb 14, 2023

BUY
$1.68 - $2.5 $22,254 - $33,117
13,247 Added 866.95%
14,775 $28,000
Q3 2022

Nov 14, 2022

BUY
$0.29 - $4.04 $249 - $3,474
860 Added 128.74%
1,528 $3,000
Q2 2022

Aug 15, 2022

SELL
$3.24 - $5.85 $29,519 - $53,299
-9,111 Reduced 93.17%
668 $2,000
Q1 2022

May 16, 2022

SELL
$4.6 - $8.83 $105,224 - $201,986
-22,875 Reduced 70.05%
9,779 $51,000
Q4 2021

Feb 14, 2022

BUY
$7.75 - $10.05 $196,594 - $254,938
25,367 Added 348.11%
32,654 $277,000
Q3 2021

Nov 15, 2021

BUY
$7.78 - $10.0 $24,592 - $31,610
3,161 Added 76.61%
7,287 $73,000
Q2 2021

Aug 16, 2021

BUY
$9.22 - $14.48 $38,041 - $59,744
4,126 New
4,126 $39,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $628M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.